Search Medical Condition
Please enter condition
Please choose location from dropdown

Drammen, Norway Clinical Trials

A listing of Drammen, Norway clinical trials actively recruiting patients volunteers.

RESULTS

Found (31) clinical trials

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with ...

Phase

0.0 miles

Learn More »

Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)

This study aims to evaluate the pharmacokinetics of posaconazole (POS) administered intravenously (IV) or orally to immunocompromised pediatric participants.

Phase

0.0 miles

Learn More »

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

This study aims to compare treatment with imipenem/relebactam/cilastatin (IMI/REL) as a fixed-dose combination (FDC) with piperacillin/tazobactam (PIP/TAZ) FDC in participants with hospital-acquired and ventilator-associated bacterial pneumonia. The primary hypothesis is that IMI/REL is non-inferior to PIP/TAZ in the incidence rate of all-cause mortality.

Phase

0.0 miles

Learn More »

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants Ages 2 to <12 Years With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Part A (IV): Group 1 (Cohort 1 and Cohort 2) (6 to <12 years) Group 2 (Cohort 1 and Cohort 2) (2 to <6 years) Part B (Oral Suspension): Group 3 (6 to <12 years) Group 4 (2 to <6 years) In Cohort 1 of Group 1 (IV) participants received ...

Phase

0.0 miles

Learn More »

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Phase

0.0 miles

Learn More »

Effect of the New Norwegian Food Based Dietary Guidelines on Chronic Diseases in Colorectal Cancer Survivors

The increased incidence and survival after treatment contributes to a rising number of people living with a previous cancer diagnosis. Cancer-survivors have an increased risk of developing other lifestyle diseases compared to an age-mathed general population. The aim of this study to examine whether a dietary changes affects health and ...

Phase N/A

0.0 miles

Learn More »

The Norwegian Drug Monitoring Study

Infliximab and other TNF-inhibitors have revolutionised the treatment of several immunological inflammatory diseases. Still, more than half of the patients either do not respond sufficiently to infliximab therapy or loose efficacy over time. The large individual variation in the serum drug concentrations on standard doses and the development of anti-drug ...

Phase N/A

0.0 miles

Learn More »

Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?

The BIOSTOP study is a prospective, open randomized, multicenter, parallel-group study to compare clinical outcome of discontinuing (interventional group) compared to continuing (control group) biologic treatment with anti-TNF in ulcerative colitis patients in clinical remission. Adult male and female patients with an established diagnosis of ulcerative colitis treated for minimum ...

Phase N/A

0.0 miles

Learn More »

Norwegian Capture the Fracture Initiative

A fracture liaison service model of care is widely recommended but data on its effectiveness regarding reduced risk of recurrent fracture and fracture related mortality are scarce. The investigators therefore aim to assess the risk of subsequent fractures and mortality after a clinical fracture in patients who present to hospitals ...

Phase N/A

0.0 miles

Learn More »

Skin-to-skin After Delivery in Preterm Infants Born at 28-32 Weeks of Gestation

Power calculations are based on a difference in Bayley Scale of Infant Development III, cognitive scale at two years corrected age of about 7,5 mean score =0.5 SD (=0,05, =0.80). Based on this analysis, 64 preterm infants are needed in each group to yield statistic significance. Allowing for withdrawals, the ...

Phase N/A

0.0 miles

Learn More »